Publications by authors named "Rashmi Kanagal-Shammana"
Article Synopsis
- * Out of 12 enrolled patients, most had FLT3 (58%) or CBL (42%) mutations; the treatment was found to be safe, as no maximum tolerated dose was reached and 83% had a positive response.
- * Common severe side effects included low platelet counts and infections, with patients showing a median overall survival of 17.5 months and FLT3 mutation clearance in 57% of cases, indicating promising results for this treatment approach.
